NVIDIA expands BioNeMo drug discovery platform with Thermo Fisher, Chai and Boltz

NVIDIA said life sciences companies are adopting its open BioNeMo platform, naming Eli Lilly, Thermo Fisher Scientific and a long list of model builders, robotics firms and lab-automation companies. The release cites an estimated $300 billion a year in industry R&D costs as the market being targeted. It is an adoption announcement with no contract values or revenue figures.

• Named partners include Thermo Fisher Scientific, Chai Discovery, Boltz, Basecamp Research and Terray Therapeutics
• Digital twin users named include Amgen and Roche
• Release cites an estimated $300 billion per year in industry R&D costs
• No contract values or revenue disclosed